Insights: Pre-Exposure Prophylaxis (PrEP) and STIs

Mar 26, 2019 | Kim Rodgers

PrEP is a medication that can be used to help prevent human immunodeficiency virus (HIV) infection. Research has shown that when taken consistently, daily PrEP can reduce the risk of HIV infection by up to 90%. The Center for Disease Control and Prevention (CDC) has recommended that PrEP be offered to individuals who are at high risk of getting HIV, including those who inject drugs, those who are HIV-negative but are in a sexual relationship with someone who is HIV-positive, and gay or bisexual men who have engaged in anal sex without a condom and are not in a monogamous relationship.

Having an STI could also increase the risk for HIV infection. The two most commonly reported STIs in the United States, Neisseria gonorrhoea (NG) and Chlamydia trachomatis (CT), increase both the risk for transmission and acquisition of HIV among men who have sex with men (MSM). Recent research by Emory’s Coalition for Applied Modeling for Prevention (CAMP) estimated that 10% of all new HIV infections among men who have sex with men (MSM) are linked to NG and CT. Offering PrEP to MSM at the time of NG/CT diagnosis is an effective and efficient way of targeting PrEP use to those at high risk for getting HIV. This targeted PrEP approach was estimated by CAMP researchers to be 1.6X as impactful as untargeted PrEP screening in preventing HIV infection among MSM. Expanding NG/CT screening for MSM at the community level and offering PrEP to those testing positive for NG/CT could reduce HIV incidence by 22% over 20 years.

Because PrEP does not prevent STIs, the public health community is concerned that individuals on PrEP may falsely perceive that they are “protected” in their sexual risk behaviors, leading to risk compensation (an increase in risk behaviors while taking PrEP) and higher rates of STIs. Current CDC PrEP guidelines recommend at least bi-annual STI screening following PrEP initiation. In addition, the guidelines recommend quarterly STI testing for sexually active persons with signs or symptoms of infection and asymptomatic MSM at high risk for recurrent bacterial STIs. Based on the modeling work by CAMP researchers, implementing the CDC PrEP guidelines with bi-annual STI screening alone could prevent 40% of new NG/CT infections over the next 10 years, and with the additional quarterly STI screening of MSM at high risk for recurrent bacterial STIs, it could reduce STI incidence even further. Diagnosis and treatment of asymptomatic NG/CT could increase 17% due to PrEP-related screening.

NG/CT diagnosis has been identified as an efficient, objective indicator of PrEP eligibility. Targeting PrEP to MSM at time of NG/CT diagnosis and implementing the CDC PrEP guidelines – with the recommended follow-up STI screening – will not only reduce the burden of HIV, but also significantly decrease STI incidence.

REFERENCES

  • U.S. Department of Health and Human Services. HIV Prevention. AIDSinfo. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/20/85/pre-exposure-prophylaxis–prep- Published November 7, 2018. Accessed March 5, 2019.
  • Centers for Disease Control and Prevention. PrEP. Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/basics/prep.html. Accessed March 5, 2019
  • Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study. Clin Infect Dis. 2017;65(5):712-718.
  • Jones J, Weiss K, Mermin J, et al. Proportion of Incident HIV Cases among Men Who Have Sex with Men Attributable to Gonorrhea and Chlamydia: A Modeling Analysis. Sex Transm Dis. 2019.
  • Kasaie P, Schumacher CM, Jennings JM, et al. Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study. BMJ Open. 2019;9(3):e023453.

637020799465370000

About Kim Rodgers

Kim Rodgers is the Communications Manager at NACCHO.

More posts by Kim Rodgers

0 Comments

Related Posts

  • National Environmental Public Health Tracking

Linking Exposures and Health Effects to Environmental...

This year, NACCHO piloted a technical assistance program focused on...

Jul 10, 2020 | Tiara Smith

Linking Exposures and Health Effects to Environmental...

2019 Profile Workforce and Finance Capacity final May 2020 Page 1
  • Press Release

NACCHO New Analysis: Changes in Local Health Department...

— Updated data highlight pre-COVID challenges and potential impact of...

Jul 10, 2020 | Andrea Grenadier

NACCHO New Analysis: Changes in Local Health Department...

Cdc badge small
  • Tools & Resources

CDC Report: Temporary Reassignment of Personnel Requests...

CDC recently updated its flexibilities guidance for recipients and applicants...

Jul 09, 2020 | Kim Rodgers

CDC Report: Temporary Reassignment of Personnel Requests...

Jennifer kertanis headshot 24152456360
  • Opportunity

Top Moments From Day Two at NACCHO 360

Welcome to the final day of NACCHO 360! Yesterday NACCHO Chief Executive...

Jul 09, 2020 | Taylarr Lopez

Top Moments From Day Two at NACCHO 360

COVID VC Screenshot
  • COVID-19
  • Tools & Resources
  • Emergency Response
  • Infectious Disease

NACCHO’s COVID-19 Virtual Community Now Available to All...

NACCHO has opened our COVID-19 Virtual Community to all local health department...

Jul 08, 2020 | Kim Rodgers

NACCHO’s COVID-19 Virtual Community Now Available to All...

Sync2020 logos horizontal 1024x304
  • HIV, STI, & Viral Hepatitis

Scholarships Available: SYNChronicity 2020 Conference –...

SYNC 2020, the National Conference for HIV, HCV, STI and LGBTQ Health, is...

Jul 08, 2020 | Julia Zigman

Scholarships Available: SYNChronicity 2020 Conference –...

  • COVID-19
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

Kaiser Family Foundation: Reduction in Sexual and...

The Kaiser Family Foundation released a new issue brief, Potential Impacts of...

Jul 08, 2020 | Julia Zigman

Kaiser Family Foundation: Reduction in Sexual and...

2000px US CDC logo
  • HIV, STI, & Viral Hepatitis

New Recommendations for Hepatitis Vaccination

CDC has released new recommendations for hepatitis A virus (HAV) vaccination,...

Jul 08, 2020 | Julia Zigman

New Recommendations for Hepatitis Vaccination

TAG Logo
  • HIV, STI, & Viral Hepatitis
  • Research & Reports

Treatment Action Group 2020 Pipeline Report Now Available

Treatment Action Group (TAG) recently published their 2020 Pipeline Report, an...

Jul 08, 2020 | Julia Zigman

Treatment Action Group 2020 Pipeline Report Now Available

Back to Top